INAB

IN8BIO, INC. (INAB) - Q1 2026 Filing Summary

Business Context and Reporting Period

This summary covers the Quarterly Report on Form 10-Q for IN8BIO, INC. for the period ended March 31, 2026. IN8BIO is a clinical-stage biopharmaceutical company focused on gamma-delta T cell product candidates for cancer and autoimmune diseases. The company is classified as a non-accelerated filer, a smaller reporting company, and an emerging growth company. All share and per-share data have been restated to reflect a one-for-thirty reverse stock split effected in June 2025.

Key Financial Metrics

Material Changes vs. Prior Period

• Reduced Net Loss: Net loss decreased by $460,000 (8.3%) compared to Q1 2025, driven primarily by lower operating expenses.
• Expense Reduction: Total operating expenses declined by $394,000. Research and Development (R&D) expenses decreased by $359,000, largely due to a $404,000 reduction in costs for the INB-400 program (suspended enrollment) and lower facility-related charges. General and Administrative (G&A) expenses remained relatively flat, decreasing by only $35,000.
• Stock-Based Compensation: Non-cash stock-based compensation expense dropped significantly by $430,000 (52%) year-over-year.
• Liquidity Position: Cash and restricted cash increased by approximately $10 million compared to the prior year period, though cash used in operating activities was $4.9 million for the quarter.

Outlook, Risks, and Management Commentary

• Going Concern Warning: The company has disclosed substantial doubt about its ability to continue as a going concern. Management states that existing cash of $21.9 million is not anticipated to fund projected operating expenses and capital expenditures for at least 12 months from the date of issuance. The company expects to incur additional losses as it advances clinical trials.
• Capital Raising Plans: To extend its runway, the company plans to raise additional capital through equity/debt offerings (including its ATM program), strategic collaborations, or licensing.
  • Potential Proceeds: The company may be eligible for up to ~$20.1 million from a milestone-driven closing of a December 2025 private placement. Additionally, up to $6.7 million could be raised from the exercise of Series C warrants and up to $2.3 million from Series B warrants.
• Operational Prioritization: The company is implementing cash preservation measures, including pipeline prioritization. Enrollment in the INB-400 Phase 2 trial for glioblastoma was suspended in September 2024 to conserve capital. Preclinical programs (INB-300, INB-500) remain paused.
• Key Risks: Risks include the inability to secure additional financing, failure of clinical trials, regulatory delays, and dependence on third-party manufacturers. The company also faces risks related to intellectual property licensing and potential dilution from future equity issuances.

Investor Verification Checklist

• Liquidity Runway: Verify the specific timeline for cash exhaustion and the status of the "substantial doubt" disclosure in the latest filings.
• Financing Milestones: Confirm the status of the milestone-driven conditions for the potential $20.1 million private placement closing related to the INB-619 product candidate.
• Warrant Exercise Activity: Monitor the exercise status of outstanding Series B and Series C warrants, as these represent potential but uncertain sources of capital.
• Clinical Trial Status: Review updates on the INB-100 Phase 1 trial (AML) and the suspended INB-400 Phase 2 trial (GBM) for any changes in enrollment or data release timelines.
• ATM Program Capacity: Check the remaining capacity under the At-The-Market (ATM) program, which had $5.9 million available as of March 31, 2026, subject to "baby shelf" limitations due to public float size.